Overview
Non-randomized, open label, Phase 1/2 dose escalation study of BS01, a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP).
Eligibility
Inclusion Criteria:
- Confirmed diagnosis of retinitis pigmentosa
- Bare light perception in at least one eye
Exclusion Criteria:
- Prior receipt of any AAV gene therapy product
- Large amplitude nystagmus